Top
Gene therapy for beta-thalassemia recommended for approval in Europe - Healing Genes
908
post-template-default,single,single-post,postid-908,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

Gene therapy for beta-thalassemia recommended for approval in Europe

Share on facebook
Share on google
Share on twitter
Share on linkedin

Europe’s Committee for Medicinal Products for Human Use has recommended that Bluebird Bio’s lentiglobin, or Zynteglo, gene therapy for beta-thalassemia be approved. The treatment inserts a copy of the beta-globin gene into bone marrow cells.

https://www.statnews.com/2019/03/29/first-gene-therapy-to-treat-rare-blood-disease-nears-european-approval/

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.